Skip to content

Keith Humphreys

4 papers in the library · 54 citations · publishing 2022-2024

Papers

Sort Most recent Most cited

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Annual Review of Psychology August 2, 2024 Keith Humphreys, Daniel Stjepanović, Wayne Hall et al. 18 citations

Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit...

Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?

Addiction June 6, 2024 Wayne Hall, Keith Humphreys, John Marsden et al. 18 citations

Abstract The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, accompanied by extensive positive media attention and private equity investment. Government regulatory bodies in Australia, Israel, Canada and the United States now permit use of psychedelics for medical purposes. In the United States, citizen action...

DOI: 10.1111/add.16575 (opens in new tab) Cannabis Legalization Recreation Parallels +2

State Cannabis Legalization and Psychosis-Related Health Care Utilization

JAMA Network Open January 25, 2023 Holly Elser, Keith Humphreys, Mathew V. Kiang et al.

Importance Psychosis is a hypothesized consequence of cannabis use. Legalization of cannabis could therefore be associated with an increase in rates of health care utilization for psychosis. Objective To evaluate the association of state medical and recreational cannabis laws and commercialization with rates of psychosis-related health care utilization. Design, Setting, and Participants...